Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
Feig SA, Ames MM, Sather HN, Steinherz L, Reid JM, Trigg M, Pendergrass TW, Warkentin P, Gerber M, Leonard M, Bleyer WA, Harris RE. Feig SA, et al. Among authors: pendergrass tw. Med Pediatr Oncol. 1996 Dec;27(6):505-14. doi: 10.1002/(SICI)1096-911X(199612)27:6<505::AID-MPO1>3.0.CO;2-P. Med Pediatr Oncol. 1996. PMID: 8888809 Clinical Trial.
Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report from the Childrens Cancer Study Group.
Feig SA, Krailo MD, Harris RE, Baum E, Holcenberg JS, Kaizer H, Steinherz L, Pendergrass TW, Saunders EF, Warkentin PL, et al. Feig SA, et al. Among authors: pendergrass tw. Med Pediatr Oncol. 1992;20(2):124-9. doi: 10.1002/mpo.2950200207. Med Pediatr Oncol. 1992. PMID: 1734217 Clinical Trial.
Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group.
Reaman GH, Sposto R, Sensel MG, Lange BJ, Feusner JH, Heerema NA, Leonard M, Holmes EJ, Sather HN, Pendergrass TW, Johnstone HS, O'Brien RT, Steinherz PG, Zeltzer PM, Gaynon PS, Trigg ME, Uckun FM. Reaman GH, et al. Among authors: pendergrass tw. J Clin Oncol. 1999 Feb;17(2):445-55. doi: 10.1200/JCO.1999.17.2.445. J Clin Oncol. 1999. PMID: 10080584 Clinical Trial.
Improved three-year disease-free survival in osteogenic sarcoma.
Bleyer WA, Haas JE, Feigl P, Greenlee TK, Schaller RT Jr, Morgan A, Pendergrass TW, Johnson FL, Bernstein ID, Chard RL Jr, Hartmann JR. Bleyer WA, et al. Among authors: pendergrass tw. J Bone Joint Surg Br. 1982;64(2):233-8. doi: 10.1302/0301-620X.64B2.6978340. J Bone Joint Surg Br. 1982. PMID: 6978340
56 results